FOLR1 Heavy-Chain-Only ADC (BCG047)

Asset ID: BCG047
Targets: FOLR1
  • Aliases:
  • FBP, FOLR, FRα
  • Modality:
  • Heavy-chain-only antibody-drug conjugate (HCAb-ADC
  • Payload Design:
  • BLD1102 linker–payload system containing BCPT02, a TOP1 inhibitor payload
  • Development Stage:
  • Preclinical
  • Indications:
  • Non-small cell lung cancer (NSCLC), ovarian cancer, endometrial cancer
  • Key Differentiation:
  • Compact HCAb format with a novel FOLR1 epitope, supporting improved tumor penetration, efficient internalization, antitumor efficacy, and broader expression-level coverage
  • Partnership Opportunity:
  • Available for licensing and co-development
获取数据包 预定会议
https://cdn.biocytogen.com/web/backend/upload/asset/image/BCG047/20260909230506124126.png (BCG047) banner

在此页面上

  • FOLR1 Heavy-Chain-Only ADC Asset Highlights
  • Preclinical Data
  • Partnership Opportunities
  • FAQs

海报

查看全部

    Related Platforms and Resources

    BCG047: A Novel FOLR1 Heavy-Chain-Only ADC for Solid Tumors

    FOLR1-Targeted ADC Strategy Across Varying Expression Levels

    • HCAb format overcoming IgG penetration limitation: Conventional IgG-based ADCs are limited by impaired core penetration in solid tumors, leaving residual tumor cells behind. BCG047 is built on a compact heavy-chain-only antibody (HCAb) format, designed for deeper tissue penetration, improving drug distribution.
    • Novel FOLR1 epitope selectivity: BCG047 targets a novel FOLR1 epitope distinct from conventional FOLR1 ADCs, supporting differentiated binding selectivity and antitumor efficacy in low-FOLR1-expressing tumors, with the potential to address a broader patient population.
    • Competitive differentiation: BCG047 combines a compact HCAb format with a novel FOLR1 epitope, supporting enhanced intratumoral penetration and antitumor activity across FOLR1 expression levels, thereby expanding the therapeutic window within the FOLR1-targeting landscape.

    RenNano® Fully Human Heavy-Chain-Only Antibody Backbone

    Built on the RenNano® platform, BCG047 utilizes a fully human heavy-chain-only antibody backbone with a compact format. This platform supports the discovery of differentiated FOLR1-binding domains without subsequent humanization and provides a modular antibody framework for ADC conjugation, developability optimization, and further half-life engineering.

    Proprietary BLD1102 Linker–Payload Design for ADC Drug Development

    BCG047 is conjugated with Biocytogen’s proprietary BLD1102 linker–payload system containing BCPT02, a topoisomerase I (TOP1) inhibitor payload designed to drive potent ADC-mediated cytotoxicity in solid tumor drug development.

    • Payload-driven cytotoxic coverage: BCPT02 combines high payload potency with strong bystander killing to eliminate both target-positive and neighboring tumor cells.
    • Developability-oriented linker design: BLD1102 linker is designed for superior hydrophilicity, controlled payload release, and high circulation stability, enhancing ADC developability and therapeutic performance.

    Excellent Preclinical Performance

    • BCG047 demonstrated strong binding and efficient internalization across tumor cells with different FOLR1 expression levels, supporting tumor engagement and intracellular payload delivery (Figure 1 & Figure 2).
    • The BCG047 FOLR1 heavy-chain-only antibody backbone showed an acceptable PK profile and favorable physicochemical properties, supporting continued ADC development (Figure 3).
    • BCG047 demonstrated robust antitumor efficacy in gastric cancer and NSCLC PDX models, with differentiated activity in the FOLR1-low-expression model (Figure 4).

    Potential Indications

    BCG047 is being developed as a FOLR1 heavy-chain-only ADC for FOLR1-expressing solid tumors, with potential indications including non-small cell lung cancer (NSCLC), ovarian cancer, and endometrial cancer, particularly in tumors with low or heterogeneous FOLR1 expression.

    Preclinical Data Highlights Supporting BCG047 FOLR1 Heavy-Chain-Only ADC Drug Development

    The supporting preclinical data package for BCG047, generated from Biocytogen internal studies, includes strong FOLR1 binding and internalization across tumor cells with different expression levels, an acceptable PK profile, favorable physicochemical properties, and antitumor efficacy in PDX and CDX models, including a FOLR1-low-expression setting. Together, these data support the development of BCG047 as a differentiated FOLR1 heavy-chain-only ADC for FOLR1-expressing solid tumors.

    BCG047 FOLR1 Antibody Demonstrates Strong Binding Across FOLR1 Expression Levels

    Binding curves showing strong FOLR1 HCAb avidity in HeLa cervical cancer and OVCAR-3 and SKOV-3 ovarian cancer cells with varying FOLR1 expression levels compared with FOLR1 benchmark analogs.

    Figure 1. Antigen binding analysis of BCG047 FOLR1 heavy-chain-only antibody across FOLR1-expressing tumor cell lines. The FOLR1 antibody backbone demonstrated strong binding avidity in HeLa cervical cancer cells, OVCAR-3 and SKOV-3 ovarian cancer cells with varying FOLR1 expression levels, showing binding activity comparable to five FOLR1-targeting benchmark analogs. These data support consistent tumor cell recognition across different FOLR1 expression contexts.
    In addition, the FOLR1 antibody backbone (HCAb-01) showed human and cynomolgus monkey cross-reactivity with high target specificity, supporting translational development and species-relevant preclinical evaluation.

    BCG047 FOLR1 Antibody Shows Efficient Internalization

    Internalization data showing efficient uptake of the BCG047 FOLR1 heavy-chain-only antibody in OVSAHO and SKOV-3 ovarian cancer cells.

    Figure 2. Internalization analysis of BCG047 FOLR1 heavy-chain-only antibody in ovarian cancer cells. At a working concentration of 17.5 nM, the FOLR1 antibody backbone (HCAb-01) demonstrated efficient internalization in OVSAHO and SKOV-3 cells, with activity comparable to five FOLR1-targeting benchmark analogs. These results support effective cellular uptake of the BCG047 antibody backbone and its suitability for intracellular payload delivery in a FOLR1 ADC format.

    BCG047 Heavy-Chain-Only Antibody Exhibits Acceptable PK and Favorable Developability

    Pharmacokinetic curves showing the exposure profile of the BCG047 FOLR1 heavy-chain-only antibody backbone after a single 6 mg/kg intravenous dose in C57BL/6 mice.

    Figure 3. Pharmacokinetic analysis of the BCG047 FOLR1 heavy-chain-only antibody in C57BL/6 mice. Each group included six mice, with each animal receiving a single intravenous dose at 6 mg/kg. The FOLR1 antibody backbone (HCAb-01) exhibited an acceptable PK profile (T1/2 = 6.5d), supporting continued FOLR1 ADC development.
    In addition, HCAb-01 showed favorable physicochemical properties and maintained consistent binding activity following stress treatments, supporting molecular stability and developability.

    BCG047 FOLR1 ADC Demonstrates Robust Antitumor Efficacy in PDX Models

    Tumor growth curves showing robust antitumor efficacy of the BCG047 FOLR1 heavy-chain-only ADC in FOLR1-high- and FOLR1-low-expression PDX models compared with matched-DAR FOLR1 ADC benchmarks.

    Figure 4. Antitumor efficacy analysis of the BCG047 FOLR1 heavy-chain-only ADC in FOLR1-expressing PDX models. BCG047 (DAR 4) was evaluated against two matched-DAR benchmark analogs in the gastric cancer and NSCLC PDX models, which represent distinct FOLR1 expression levels. BCG047 demonstrated potent tumor growth inhibition across both models, showing a particularly marked advantage over the benchmarks in the FOLR1-low setting. 
    In addition, robust activity in a FOLR1-moderate CDX model confirms its broad therapeutic potential across variable target expression levels.

    Explore BCG047 Partnership Opportunities

    Biocytogen welcomes partnership discussions to further evaluate this FOLR1 Heavy-Chain-Only ADC asset.

    Frequently Asked Questions (FAQs) About BCG047 FOLR1 Heavy-Chain-Only ADC

    1. What makes FOLR1 an important target for cancer therapies?

    Folate receptor alpha (FOLR1) is a clinically validated tumor-associated antigen (TAA) that is heavily overexpressed in epithelial malignancies, such as ovarian, lung, and breast cancers. Because it exhibits very limited distribution in normal, healthy tissues, it provides a highly attractive target for precision solid tumor therapeutics with significant commercial potential.

    2. What are the main limitations of first-generation FOLR1 ADCs?

    First-generation FOLR1 therapies, such as Elahere (mirvetuximab), typically require a high threshold of FOLR1 expression (>75%) to be effective. Furthermore, traditional ADCs utilize a bulky conventional IgG1 antibody format that struggles to physically penetrate dense solid tumors, severely limiting their efficacy in low-FOLR1 tumor microenvironments.

    3. How does Biocytogen's BCG047 differentiate itself from other FOLR1-targeted therapies?

    BCG047 stands out by shrinking the delivery vehicle itself. Unlike conventional ADCs that use bulky IgG1 formats, BCG047 is built on a compact, fully human heavy-chain-only antibody (HCAb) structure derived from the RenNano® platform. This streamlined physical footprint unlocks deep tissue penetration, allowing the therapy to reach the hypoxic tumor core that standard ADCs cannot access. Furthermore, BCG047 targets a novel epitope, helping overcome competitive binding challenges in the crowded FOLR1 landscape.

    4. What linker-payload strategy is used for BCG047?

    BCG047 is conjugated with Biocytogen’s proprietary BLD1102 linker–payload system containing BCPT02, a topoisomerase I (TOP1) inhibitor payload. The BLD1102 linker–payload design is engineered to support potent ADC-mediated cytotoxicity, controlled payload release, hydrophilicity, circulation stability, and overall ADC developability.